To genetically target B-ALL glucose uptake, therefore, we generated primary BCR-Abl B-ALL cells from Glut1fl/fl/Ubi-Cre-ERT2 mice to enable inducible deletion of glucose transporter Glut1 upon treatment with 4-hydroxytamoxifen (4-OHT). The gene discussed is SLC2A1; the disease is acute lymphoblastic leukemia.